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BACKGROUND AND PURPOSE
Fluoxetine, a selective serotonin reuptake inhibitor, elevates brain concentrations of the neuroactive progesterone metabolite
allopregnanolone, an effect suggested to underlie its use in the treatment of premenstrual dysphoria. One report showed
fluoxetine to activate the aldo-keto reductase (AKR) component of 3α-hydroxysteroid dehydrogenase (3α-HSD), which
catalyses production of allopregnanolone from 5α-dihydroprogesterone. However, this action was not observed by others. The
present study sought to clarify the site of action for fluoxetine in elevating brain allopregnanolone.
EXPERIMENTAL APPROACH
Adult male rats and female rats in dioestrus were treated with fluoxetine and their brains assayed for allopregnanolone and its
precursors, progesterone and 5α-dihydroprogesterone. Subcellular fractions of rat brain were also used to investigate the
actions of fluoxetine on 3α-HSD activity in both the reductive direction, producing allopregnanolone from
5α-dihydroprogesterone, and the reverse oxidative direction. Fluoxetine was also tested on these recombinant enzyme
activities expressed in HEK cells.
KEY RESULTS
Short-term treatment with fluoxetine increased brain allopregnanolone concentrations in female, but not male, rats. Enzyme
assays on native rat brain fractions and on activities expressed in HEK cells showed fluoxetine did not affect the AKR
producing allopregnanolone from 5α-dihydroprogesterone but did inhibit the microsomal dehydrogenase oxidizing
allopregnanolone to 5α-dihydroprogesterone.
CONCLUSIONS AND IMPLICATIONS
Fluoxetine elevated allopregnanolone in female rat brain by inhibiting its oxidation to 5α-dihydroprogesterone by a
microsomal dehydrogenase. This is a novel site of action for fluoxetine, with implications for the development of new agents
and/or dosing regimens to raise brain allopregnanolone.
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Introduction
Already widely prescribed as antidepressants, selective seroto-
nin reuptake inhibitors (SSRIs), such as fluoxetine, have gained
increasing acceptance since the 1990s (Steiner et al., 1995) as
treatments for premenstrual dysphoric disorder (PMDD) and
the more common but loosely defined premenstrual syn-
drome (see Marjoribanks et al., 2013). The former is a debili-
tating condition (Dennerstein et al., 2010) that includes both
mood and physical symptoms such as irritability, anxiety,
outbursts of anger, fatigue, sleep disturbance andhyperalgesia,
and is thought at least in part to be triggered by thewithdrawal
of endogenous progesterone (see Backstrom et al., 2003). One
explanation for the utility of fluoxetine and other SSRIs in the
treatment of PMDD is their ability to raise concentrations of
the neuroactive progesterone metabolite allopregnanolone in
the CNS, an effect documented in the brains of male rats
(Uzunov et al., 1996) andmice (Pinna et al., 2003) and in both
male and female human CSF (Uzunova et al., 1998). Studies in
male mice have shown the acute, fluoxetine-induced increase
in brain allopregnanolone to occur at doses lower than those
required for inhibition of 5-HT uptake, providing a possible
explanation for the rapid response of PMDD patients to low
doses of this drug (see Pinna et al., 2006 and Discussion).
Indeed, there is increasing evidence that the effectiveness of
SSRIs and certain other drugs in the treatment of a range of
anxiety and depressive disorders may be explained, at least in
part, by their ability to raise brain allopregnanolone concen-
trations (see Schule et al. 2014).
The anxiolytic, anticonvulsant and sedative steroid allo-
pregnanolone is a potent enhancer of the actions of the
inhibitory transmitter GABA at GABAA receptors (see Wang,
2011). Moreover, withdrawal of progesterone in rats, either
naturally as occurs during the ovarian cycle or by termination
of pseudopregnancy or experimentally, after treatment with
exogenous steroid, leads to changes in GABAA receptor
subunit expression which predispose to anxiety, seizures and
hyperalgesia (Smith et al., 1998a,b; Griffiths and Lovick,
2005). These changes are mediated not directly by progester-
one but rather by its metabolite allopregnanolone (Smith
et al., 1998a; Gulinello et al., 2001; Turkmen et al., 2011).
Thus, studies in rat suggest PMDD is triggered by progester-
one withdrawal and mediated by a fall in the concentration
of its neuroactive metabolite allopregnanolone in the brain,
providing a rationale for treatment with fluoxetine.
Synthesis of allopregnanolone from progesterone is cata-
lysed by two enzyme systems (see Figure 1): a 5α-reductase
producing 5α-dihydroprogesterone from progesterone and
3α-hydroxysteroid dehydrogenase (3α-HSD) activities inter-
converting 5α-dihydroprogesterone and allopregnanolone
(see Compagnone and Mellon, 2000). In rat brain, the pro-
gesterone type 1 5α-reductase (SRD5A1) is an NADPH-
dependent microsomal enzyme catalysing the irreversible
reduction of progesterone to 5α-dihydroprogesterone. By
contrast, 3α-HSD consists of two activities that are reversible
in vitro: one cytosolic and NADP(H)-linked and the other
NAD(H)-linked and found in particulate fractions. The cyto-
solic 3α-HSD activity is an aldo-keto reductase (AKR), with a
higher affinity for NADPH than NADP+, ensuring that the
enzyme functions predominantly as a ketosteroid reductase
in vivo (see Penning, 2011). Only one gene has been identified
for rat AKR, the type 1 3α-HSD liver enzyme AKR1C9 (Lin
et al., 1999). The particulate NAD(H)-linked 3α-HSD activity
is assigned to the short-chain dehydrogenase/reductase (SDR)
family, which under normal cellular NAD+ : NADH ratios
would be expected to function predominantly as oxidases
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(Miller and Auchus, 2011; Penning, 2011). Those responsible
for oxidation of 3α-hydroxysteroids such as allopregna-
nolone have been identified as retinol dehydrogenase (RoDH)
enzymes in human prostate (Bauman et al., 2006) and these
microsomal RoDH enzymes are found also in rat (Napoli,
2001; Belyaeva and Kedishvili, 2006), where the predominant
form in brain appears to be RoDH2 (Chai et al., 1995). Of the
above enzymes, the 5α-reductase has the lowest Km and is
accepted as the first and rate-limiting step in the synthesis of
allopregnanolone from progesterone (see Karavolas and
Hodges, 1990).
Depending on brain region, the fluoxetine-induced eleva-
tion of allopregnanolone concentration in adrenalectomized
and castrated male rat brains, as first reported by Uzunov et al.
(1996), was accompanied by a fall or no change in
5α-dihydroprogesterone and no change in progesterone,
implying an effect of the drug on 3α-HSD activity. Further
evidence for 3α-HSD as a site of action for fluoxetine was
obtained from experiments that showed this drug to cause an
increased accumulation of allopregnanolone in brain slices
loaded with 5α-dihydroprogesterone in vitro (Uzunov et al.,
1996). Subsequently, Griffin and Mellon (1999) described an
activation (decrease in Km) of purified recombinant rat liver
type 1 (AKR1C9) and human type 3 (AKR1C2) 3α-HSD
enzymes by fluoxetine, with no effect on rat type 1
5α-reductase activity in transfected cells. In contrast, Trauger
et al. (2002) found no effect of fluoxetine or other SSRIs on the
purified recombinant human type 3 (AKR1C2) 3α-HSD
enzyme. Moreover and as mentioned above, 5α-reductase is
considered the rate-limiting step in the synthesis of allopreg-
nanolone from progesterone in brain and so activation of AKR
would not be expected to raise concentrations of this metabo-
lite in vivo. In an attempt to resolve these discrepancies and
identify the mechanism by which fluoxetine elevates brain
allopregnanolone, we have first investigated the effects of this
drug on the concentration of allopregnanolone and its precur-
sors progesterone and 5α-dihydroprogesterone in male and
female rat brain, using short-term treatmentwith a lowdose of
this drug. Female rats were treatedwith fluoxetine at dioestrus,
the stage of the ovarian cycle when secretions of progesterone,
5α-dihydroprogesterone and allopregnanolone are in decline
(Ichikawa et al., 1974; Holzbauer, 1975). Using the same con-
centration of fluoxetine as employed in the conflicting reports
of Griffin andMellon (1999) and Trauger et al. (2002), we then
compared the effects of this drug on the native reducing and
oxidizing 3α-HSD enzyme activities of male rat brain in vitro.
We usedmale rat brains for assays of native enzyme activity to
reduce errors that might be caused by fluctuations in 3α-HSD
activity during the ovarian cycle (see Karavolas and Hodges,
1990). For comparison, the latter investigations of native
3α-HSD included norfluoxetine, the major metabolite of
fluoxetine, and imipramine, a tricyclic antidepressant. Finally,
the actions of fluoxetine, norfluoxetine and imipramine were
also tested on AKR and SDR (RoDH) activities of 3α-HSD
expressed in transfected cells. Our results indicate that SSRIs
elevate allopregnanolone in brain by inhibiting its oxidation
back to 5α-dihydroprogesterone.
Methods
Animals
All animal care and experimental procedures were under-
taken in accordance with the UK Animals (Scientific Proce-
dures) Act 1986 and with the approval of the Animal Ethics
Committee at the University of Birmingham. Studies are
reported in accordance with the ARRIVE guidelines for
reporting experiments involving animals (Kilkenny et al.,
2010; McGrath et al., 2010). A total of 27 animals were used
in the work described here.
Wistar rats, (males and females, 200–250 g body weight,
10–12 weeks old; from Charles River, UK), were housed in
groups of two or three at 21 ± 1°C and a 12 h light/dark cycle
(lights on at 07:00 h) with free access to food and water. Daily
vaginal smears were taken at approximately 09:15 h from the
females to establish their oestrus cycle stage (Brack et al., 2006)
and to check for at least two normal cycles before the start of
experiments. A final smear was taken after rats had been killed
for brain samples, in order to confirm the cycle stage.
Treatment with fluoxetine
Fluoxetine hydrochloride (1.75 mg·kg−1 i.p.) or the saline
vehicle were administered to rats at 16:30–17:00 h on the
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Figure 1
Synthesis of allopregnanolone from progesterone. A 5α-reductase
enzyme produces 5α-dihydroprogesterone from progesterone utiliz-
ing NADPH as a co-factor. The activities of 3α-HSD can then either
reduce 5α-dihydroprogesterone further to allopregnanolone or
oxidize this allopregnanolone back to 5α-dihydroprogesterone. The
reductive 3α-HSD in vivo is a cytosolic AKR utilizing NADPH as a
co-factor whereas the oxidative 3α-HSD is a microsomal SDR, char-
acterized as a RoDH and utilizing NAD+.
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evening prior to collection of brain samples, when the female
rats were in early dioestrus. An additional dose was given at
09:00–10:00 h on the following morning (late dioestrus for
the females) and animals killed 1 h later by decapitation. The
whole brains minus olfactory lobes were rapidly removed,
stripped of meninges, frozen on dry ice and stored at –80°C
until analysis.
Preparation of subcellular brain fractions
Whole male rat brains were homogenized using a Dounce
homogenizer in 10 vol of ice-cold 5 mM HEPES buffer (pH
7.4) containing 0.32 M sucrose, one cOmplete® EDTA-free
protease inhibitor cocktail tablet per 250 mL plus phenylme-
thyl sulphonyl fluoride (0.1 mM). This homogenate was cen-
trifuged at 1000× g for 10 min at 4°C to yield the supernatant
fraction S1 and pellet fraction P1 (nuclear). The pellet was
resuspended in 5 vol of ice-cold 5 mM HEPES buffer (pH 7.4)
containing 0.32 M sucrose and centrifuged at 1000× g at 4°C
for a further 10 min. The resulting supernatant was pooled
with S1. The pooled supernatant fraction was then centri-
fuged at 8000× g for 10 min at 4°C to yield a supernatant
fraction S2 and pellet fraction P2 (mitochondrial). The
remaining supernatant was centrifuged at 110 000× g for
60 min at 4°C to produce a supernatant cytosolic fraction S3
and pellet fraction P3 (microsomal). Fractions were frozen in
dry ice and stored at −80°C. The protein content of each
fraction was determined using the method of Bradford
(1976), with BSA as a standard.
Expression of recombinant enzymes
Plasmids pcDNA3 AKR1C9 (Ratnam et al., 1999) and pcDNA3
RODH4 LacZ (Bauman et al., 2006) were a gift from Professor
T Penning (University of Pennsylvania, USA) and used to
transfect HEK293 (HEK) cells cultured in DMEM supple-
mented with 10% fetal calf serum (FCS; heat-inactivated),
2 mM L-glutamine, 0.5 IU·mL−1 penicillin and 50 μg·mL−1
streptomycin. For transfection, the AKR1C9 and RoDH4 con-
structs were complexed with 10 μM polyethylenimine in
Opti-MEM medium (Ehrhardt et al., 2006) and after 5 h, this
medium replaced with DMEM containing 1% FCS. Following
further culture for 24 h, the cells were washed with PBS before
harvesting by trypsinization, centrifugation and a further
wash in ice-cold PBS. They were then resuspended in 500 μL
of SET buffer (250 mM sucrose, 1 mM EDTA and 50 mM
Tris-HCl, pH 7.4 containing one cOmplete EDTA-free pro-
tease inhibitor cocktail tablet per 50 mL) and sonicated (4 ×
10 s) on ice. Nuclei and unbroken cells were removed by
centrifugation (1000× g, 5 min, 4°C) and the lysate then
centrifuged at 100 000× g for 60 min at 4°C to obtain a
supernatant cytosolic fraction. To remove contaminating
cytosolic proteins, the membranes were resuspended in
1.5 mL of SET buffer and centrifuged (100 000× g for 60min).
The membranes were finally resuspended in 750 μL of SET
buffer. As for native brain fractions, protein content was
determined (Bradford, 1976) and fractions stored at −80°C.
TLC
Samples were applied to aluminium backed, silica gel
60-coated TLC plates and developed in one of the following
solvent systems: (A) cyclohexane : n-butyl acetate 1:2 (v v−1);
(B) cyclohexane : ethyl acetate 3:2 (v v−1); or (C) chloro-
form : ether 10:3 (v v−1). When necessary, the separated
3H-labelled steroids were visualized by exposing TLC plates to
Fujifilm BAS-TR2040S imaging plates (Raytek Scientific Ltd.,
Sheffield, UK), which were then scanned in a Typhoon 9410
variable mode phosphorimager (GE Healthcare, Amersham,
UK). Unlabelled steroid reference standards (50 μg) were visu-
alized by exposure to iodine vapour.
Measurement of brain steroids
Free steroids were extracted from brain for identification and
assay by gas capillary chromatography-electron impact mass
spectrometry (GC-EIMS) as described by Ebner et al. (2006).
Each brain was homogenized with a Polytron homogeniser in
5 vol of ice-cold 5 mM KH2PO4 buffer (pH 7) then dripped
into 20 vol 3% v v−1 acetic acid in ethanol 96% (w v−1) with
sonication. The extract was centrifuged (28 000× g, 30 min,
25°C) and the supernatant de-lipidated by partitioning three
times against 10 vol iso-octane. After drying down under
vacuum and redissolving in 2 vol of 60% ethanol, the extract
was further cleaned by passage through a 60 mg Oasis
hydrophilic-lipophilic balanced (HLB) cartridge. Extracts
were then dried under vacuum and redissolved in 20%
ethanol before loading onto a 60 mg oasis mixed-mode anion
exchange (MAX) cartridge, in order to separate free steroids
from conjugates. After washing the MAX cartridge with 20%
ethanol, the free steroids could be eluted in 4 mL ethyl
acetate, dried down under nitrogen and stored in 1 mL 96%
ethanol at −20°C until analysis.
Before derivatization for GC-EIMS analysis, the brain
steroids were dried down under nitrogen together with the
internal standard 16-dehydropregnenolone (50 ng). Meth-
oxyamine hydrochloride (MO-HCl; 200 μL; 2% w v−1 in pyri-
dine) was then added and samples incubated at 60°C for 1 h.
This was followed by 100 μL of trimethylsilyl imidazole and a
further incubation for 4 h at 120°C. Pyridine was then
removed under nitrogen and the residue redissolved in 1 mL
cyclohexane and washed twice against 0.5 mL of water.
Finally, the cyclohexane was evaporated under nitrogen and
the MO-trimethylsilyl ether derivatives redissolved in 5 μL of
the same solvent ready for injection onto the GC-EIMS. Cali-
bration standards at 0.625–10 ng were also derivatized for all
steroids and with each set of samples.
All analyses were carried out on a Shimadzu 17A GC fitted
with a 30 m long Zebron wall-coated open tubular column
(Phenomenex, Macclesfield, UK) and coupled to a quadruple
5050A MS (Shimadzu, Milton Keynes, UK). Samples were
injected in splitless mode at 280°C and a pressure of 200 kPa
for 2 min. Thereafter, the pressure was decreased to 34.2 kPa
for 5 min, followed by a rise of 6.5 kPa·min−1 to 81 kPa. After
0.33 min at this pressure, the gradient was set at
1.6 kPa·min−1 to a final pressure of 111.7 kPa, which was held
for 2 min. The oven temperature was at 70°C for 5 min and
then rose at 30°C·min−1 to 220°C. After 0.33 min, the gradient
was 5°C·min−1 to 315°C, which was held for 10 min. The
interface temperature was constant at 315°C.
For maximum sensitivity, the MS was run in selective
ion monitoring mode, with two diagnostic ions for
each steroid as follows: allopregnanolone (388 and
298), 16-dehydropregnenolone (415 and 384), 5α-
dihydroprogesterone (343 and 288), progesterone (372 and
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341). Steroids were only considered identified if the appro-
priate ions eluted at the same retention time and with the
same ion ratios as shown by the standard compound (see
Ebner et al., 2006). Quantitation was achieved by integrating
these ion peaks and those for the internal standard and then
comparing this response ratio with that obtained for the
calibration standards.
Enzyme assays
All enzyme assays were performed in triplicate at 37°C and in
100 mM potassium phosphate buffer (pH 7.4) containing
0.05 w v−1 BSA and 20 000 DPM (0.4 nM) of 3H-substrate in a
total volume of 250 μL. For saturation assays, the 3H-substrate
was increased to 40 000 DPM and combined with different
concentrations of the non-radioactive steroid over the range
0.05–1.0 μM. Preliminary experiments established initial rate
conditions, linear with respect to protein content and incu-
bation time. Assay mixtures were set-up on ice and the incu-
bations initiated by the addition to a final concentration of
1 mM of the cofactor β-NADPH or NAD+ to reductive or
oxidative assays respectively. Buffer blanks and boiled sample
controls were included in each assay. After the incubation,
samples were returned to the ice bath and extracted with
1 mL of isooctane : ethyl acetate (1:1 v v−1) containing
0.5 μg·mL−1 of non-radioactive product steroid. This upper
solvent layer was then dried down under nitrogen
and spotted onto TLC plates for separation of substrate
and product steroids. Outer lanes were spotted with
non-radioactive standards. Assays of the reduction of
5α-dihydroprogesterone to allopregnanolone employed
solvent system A to develop the plates whereas assays of the
oxidation of allopregnanolone to 5α-dihydroprogesterone
employed solvent system C. Once developed, the outer lanes
were cut off and stained to identify the location of the
product steroid. The corresponding regions in the sample
lanes could then be cut out and placed in scintillation vials
containing Ecoscint H (National Diagnostics, Hessle, UK) for
measurement of radioactivity.
Data analysis and statistical procedures
Diagnostic ion peaks on GC-EIMS traces were displayed using
Shimadzu class 5000 software for manual integration. Phos-
phor images of 3H-labelled TLC plates were assessed using
ImageQuant software (GE Healthcare). For enzyme assays,
saturation with increasing concentrations of substrate or inhi-
bition by increasing concentrations of fluoxetine was esti-
mated by non-linear curve fitting in GraphPad Prism,
(GraphPad Software, Inc., La Jolla, CA, USA) with 95% confi-
dence limits on the parameters. Student’s unpaired t-test was
used to evaluate the significance of differences in brain con-
centrations of steroids between vehicle and fluoxetine-treated
rats and of enzyme inhibition at single drug concentrations.
Materials
Unless stated otherwise, all drugs, chemicals and reagents
were purchased from (Sigma-Aldrich, Gillingham, UK or
from VWR, Lutterworth, UK) and were of analytical grade.
Solvents for brain steroid extraction and analysis by GC-EIMS
were redistilled before use. The Oasis HLB andMAX cartridges
were from Waters Corporation (Milford, MA, USA) while
the silica gel 60-coated TLC plates came from VWR. Silanized
glassware was used throughout. Non-radioactive standard
steroids were purchased from Sigma-Aldrich or Steraloids
Inc. (Newport, RI, USA) and [1,2,6,7-3H(N)]-progesterone
(3666.7 GBq·mmol−1) from PerkinElmer (Buckinghamshire,
UK). The latter was converted enzymically to [3H]-5α-
dihydroprogesterone and [3H]-allopregnanolone by incuba-
tion at 250 nM with 10 vol homogenates of whole rat brain
in 50 mM potassium phosphate buffer (pH 7.4) for 2 h at
37°C. The cofactor NADPH and dithiothreitol were each
added at a final concentration of 1 mM. Steroids were
extracted from the incubation with an equal volume of ethyl
acetate : isooctane (1:1 v v−1) then dried down and spotted
onto TLC plates for separation in solvent system A. Marker
lanes spotted with non-radioactive standards were stained to
reveal the location of the desired 3H-steroids, which were
then cut out and eluted with 2 mL ethanol followed by 2 mL
ethyl acetate. These eluates were dried down and spotted
again onto TLC plates for further purification: [3H]-
5α-dihydroprogesterone in solvent system B and [3H]- allo-
pregnanolone in solvent system C. Each label gave a single
peak at Rf values coinciding with the appropriate non-
radioactive standard.
Results
Rat brain steroids following treatment
with fluoxetine
The steroids progesterone, 5α-dihydroprogesterone and allo-
pregnanolone could be detected in the brains of both
male rats (n = 4) and female rats (n = 6) at late dioestrus,
although at around 10-fold lower concentrations in
the males. Treatment of female rats in dioestrus with fluox-
etine increased brain allopregnanolone concentrations
(P = 0.035 in comparison with vehicle-treated controls)
but no significant change in progesterone (P = 0.850) or
5α-dihydroprogesterone (P = 0.054). By contrast, when the
same steroids were measured in the brains of male rats given
the same treatment with fluoxetine, there were no significant
changes in the concentrations of progesterone (P = 0.625),
5α-dihydroprogesterone (P = 0.960) or allopregnanolone
(P = 0.416) (Figure 2).
Actions of fluoxetine on progesterone
metabolism in subcellular fractions of
rat brain
Subcellular fractions of male rat brain showed the reducing
activity of 3α-HSD, producing allopregnanolone from
5α-dihydroprogesterone, to be enriched in the cytosol
whereas the oxidizing activity catalysing the reverse reaction
was mostly particulate, with the highest activity in the micro-
somal fraction (Figure 3). When tested at 50 μM, fluoxetine
had no effect on the reducing activity in the cytosol but
inhibited the microsomal oxidation of allopregnanolone to
5α-dihydroprogesterone (Figure 4). Further assays of this
microsomal oxidative activity over a range of fluoxetine con-
centrations gave an IC50 of 240 μM (Figure 5). When tested at
this IC50 over a range of substrate allopregnanolone concen-
trations, fluoxetine was found to cause a non-competitive
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inhibition, with a significant decrease in Vmax (control 51.48 ±
14.69 vs. fluoxetine 19.37 ± 3.58 nmol·mg−1 protein min−1)
but not Km (control 0.62 ± 0.34 vs. fluoxetine 0.44 ± 0.17 μM;
all values ± 95% confidence limits). When tested at the IC50 of
240 μM for fluoxetine, a significant (P < 0.001) inhibition of
microsomal 3α-HSD oxidative activity was also seen with
norfluoxetine (50.32 ± 1.56%) and imipramine (43.74 ±
1.07%) and confirmed for fluoxetine (51.78 ± 1.99%) in com-
parison with controls (all values mean ± SEM % control).
Actions of fluoxetine on AKR1C9 and RoDH4
activities expressed in HEK cells
When tested at 50 μM, fluoxetine had no effect on the reduc-
tion of 5α-dihydroprogesterone to allopregnanolone cata-
lysed by the cytosol of HEK cells transfected with the
plasmid for rat AKR1C9 (Figure 4A). In contrast and as
found in the native microsomal fraction of rat brain, fluox-
etine inhibited the oxidation of allopregnanolone to
5α-dihydroprogesterone catalysed by the membrane fraction
of HEK cells transfected with the plasmid for human RoDH4
(Figure 4B). Assays of this RoDH4 activity over a range of
fluoxetine concentrations gave a best fit to a biphasic inhibi-
tion, with estimated IC50 values of 140 and 1466 μM
(Figure 5B). When tested at the IC50 value of 240 μM found
previously for the effect of fluoxetine on native rat brain
microsomes, a significant (P < 0.005) inhibition of RoDH4
oxidative activity was also seen with norfluoxetine (37.75 ±
0.95%) and imipramine (25.45 ± 0.04%) and confirmed for
fluoxetine (55.43 ± 1.91%) in comparison with controls (all
values mean ± SEM % control).
Discussion and conclusions
The present study found the reducing and oxidizing
activities of 3α-HSD to have distinct subcellular distri-
butions in adult rat brain, in agreement with previous obser-
vations (Rommerts and Van der Molen, 1971; Krause and
Karavolas, 1980). The activity catalysing reduction of
5α-dihydroprogesterone to allopregnanolone was predomi-
nantly cytosolic and presumably the AKR as purified by
Penning et al. (1985). We found fluoxetine at 50 μM to have
no effect either on this native enzyme or on the rat liver type
I 3α-HSD AKR1C9 activity expressed in HEK cells. These
results contradict the report of Griffin and Mellon (1999),
who found this concentration of fluoxetine to activate
(decrease the Km of) the cloned and purified recombinant
AKR1C9 protein catalysing the production of allopregna-
nolone from 5α-dihydroprogesterone and to have the same
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Figure 2
Effect of fluoxetine (FLX) treatment on the concentrations of proges-
terone (PROG), 5α-dihydroprogesterone (5α-DHPROG) and allo-
pregnanolone (ALLO) in the brains of (A) male rats and of (B) female
rats at late dioestrus (note difference in scale of y-axes). Two doses of
fluoxetine hydrochloride (1.75 mg·kg−1 i.p.) were administered: one
at 16:30–17:00 h on the day prior to collection of brain samples and
another at 09:00–10:00 h on the following day 1 h before killing the
animals. Vehicle-treated rats received an injection of the saline
vehicle alone. All values mean ± SEM (n ≥ 4). *P < 0.05, significantly
different to vehicle-treated control.
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Figure 3
Activities of 3α-HSD in subcellular fractions of adult male rat brain: H0
whole homogenate, P1 nuclear, P2 mitochondrial, P3 microsomal and
S3 cytosol. Reductive activity was measured by the conversion of
5α-dihydroprogesterone (5α-DHPROG) to allopregnanolone (ALLO)
in the presence of NADPH and oxidative activity by the reverse
reaction in the presence of NAD+. Activities are shown as mean ± SEM
(n = 5) from assays in triplicate.
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effect on the human AKR1C2 enzyme, an orthologue of the
rat AKR1C9 (Lin et al., 1999). However, our results are con-
sistent with the observations of Trauger et al. (2002), who
found no effect of fluoxetine at 50 μM on the purified
recombinant human AKR1C2 enzyme and suggested that the
results of Griffin and Mellon (1999) might have been caused
by polymers from the Prozac (Sigma-Aldrich) tablets used by
the latter authors as a source of fluoxetine acting as molecular
crowding agents and increasing the effective concentration of
substrate in the assays.
In contrast to the lack of effect of fluoxetine on reductive
3α-HSD activity, the present study identified an inhibitory
effect on the oxidative 3α-HSD activity, both in rat brain
microsomal fractions and in the membranes of HEK cells
transfected with human RoDH4. We were unable to obtain
plasmid DNA for rat RoDH but human RoDH4 is the pre-
dominant form expressed in brain and shows 71% sequence
identity to the rat RoDH2 (Belyaeva and Kedishvili, 2006),
which is the predominant form expressed in the brain of this
species (Chai et al., 1995) and displays 3α-HSD oxidative
activity (Hardy et al., 2000). Moreover, protein sequences
of human RoDH4 (also named RDH16; NCBI Reference:
075452.2) and rat RoDH2 (NCBI Reference: NP_954678.1)
display 93 and 95% identical or related amino acid residues in
the active site and the steroid binding site respectively. Inhi-
bition of RoDH4 by fluoxetine in the present study gave a
best fit to a biphasic curve suggesting multiple drug binding
sites, as might be expected for this multimeric protein (see
Liden and Eriksson, 2006; Penning, 2011). In contrast, inhi-
bition of the oxidative 3α-HSD activity in rat brain microso-
mal fractions by fluoxetine gave a best fit to a single site. This
difference between the native and expressed RoDH activities
may be due to an averaging effect of isoenzymes in the former
preparation, because at least one other RoDH has been
detected in rat brain (Chai et al., 1995). There is also the
possibility that RoDH4 requires a substrate binding protein
for optimal activity, as appears to be the case for RoDHs (see
Liden and Eriksson, 2006; Napoli, 2012) and which may be
lacking in the HEK cells we used for expression of this
enzyme. The inhibition of RoDH4 activity by fluoxetine
revealed in the present study requires further investigation as
to its mechanism of action. Nevertheless and in addition to
the current relevance to the treatment of premenstrual
dysphoria, the inhibition of RoDH4 reported here also sug-
gests a possible use for fluoxetine in treating androgen-
dependent diseases; by reducing the formation of 5α-
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Figure 4
Effect of fluoxetine (FLX) at 50 μM on 3α-HSD activities: (A)
the reducing activity producing allopregnanolone from
5α-dihydroprogesterone in male rat brain cytosol or expressed
AKR1C9 and (B) the oxidizing activity producing 5α-
dihydroprogesterone from allopregnanolone in male rat brain micro-
some fractions or expressed human RoDH4. Activities are shown as
mean ± SEM (n ≥ 4) from assays in triplicate; *P < 0.01, **P < 0.001
compared with control.
Figure 5
Effect of increasing concentrations of fluoxetine (FLX) on the oxidiz-
ing 3α-HSD activity producing 5α-dihydroprogesterone from allo-
pregnanolone in (A) male rat brain microsomes (n = 4 brains) and (B)
expressed human RoDH4 (n = 4 assays). Each assay was performed in
triplicate and the overall means shown ± SEM (if not visible smaller
than symbol for mean). Best fit curves are shown giving IC50 values
(with 95% confidence limits in brackets) as follows: (A) 240 μM
(216–268 μM) and (B) 174 μM (36–138 μM; fraction 0.34 of total
activity) plus 1466 μM (1035–2070 μM).
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dihydrotestosterone from 5α-androstan-3α,17β-diol (Bauman
et al., 2006). However, inhibition of RoDH could also alter
vitamin A metabolism, depressing the synthesis of all-trans-
retinoic acid (Napoli, 2012) and may explain the decrease in
bone mineral density seen on chronic treatment with fluox-
etine (Rizzoli et al., 2012), especially in postmenopausal
women (Studd, 2011).
Short-term treatment of female rats at dioestrus with
fluoxetine produced changes in brain steroids consistent with
the above observations in vitro. Thus, inhibition of allopreg-
nanolone oxidation in the brain by fluoxetine treatment
elevates the concentration of this steroid without a signifi-
cant effect on 5α-dihydroprogesterone. Our results differ in
the latter respect from those of Uzunov et al. (1996), who
found the fluoxetine-induced elevation of allopregnanolone
in whole male rat brain (but not all individual brain regions)
to be accompanied by a fall in 5α-dihydroprogesterone con-
centration. Moreover, in contrast to the present results with
females and to the previous results of Uzunov et al. (1996)
with males, we failed to observe a fluoxetine-induced eleva-
tion of allopregnanolone in whole male rat brain. This dis-
crepancy is unlikely to be due to procedural differences in the
extraction and assay of brain steroids because the concentra-
tions of allopregnanolone measured in whole brain of
vehicle-treated male rats in the present study were compara-
ble with those (0.8 ng·g−1) reported by Uzunov et al. (1996).
However, Uzunov et al. (1996) used a dose of fluoxetine
10-fold higher than that employed in the present study.
Taken together with the observations of Uzunov et al. (1996),
therefore, our results suggest that female rats may be more
sensitive to the brain allopregnanolone elevating action of
fluoxetine than males. Clinical evidence also indicates that
women are more sensitive to SSRIs such as fluoxetine, but not
after the menopause (Kornstein et al., 2000; Khan et al., 2005;
Pinto-Meza et al., 2006). The sex difference in responses to
the low dose of fluoxetine reported here is unlikely to be due
to differences in RoDH enzyme structure because male rat
brain microsomal fractions were used to reveal the inhibitory
effect of fluoxetine on the oxidation of allopregnanolone to
5α-dihydroprogesterone and a similar effect was observed on
the overexpressed RoDH4 enzyme. More likely, the sex dif-
ference in response to fluoxetine reflects a disparity in the
preponderant source of brain allopregnanolone. In male rat
brain, where progesterone appears to derive predominantly
from synthesis within this tissue rather than from plasma
(Corpechot et al., 1993), the 5α-reductase enzyme would be
the rate-limiting step in the production of allopregnanolone
(see Introduction) and concentrations of this steroid expected
to remain largely unaffected by inhibition of its oxidation
back to 5α-dihydroprogesterone. Conversely, in female
rat brain, the higher concentrations of progesterone,
5α-dihydroprogesterone and allopregnanolone derive pre-
dominantly from the ovaries via the plasma (Corpechot et al.,
1993). If the supply of allopregnanolone from the plasma
exceeded that produced within the brain from progesterone
in our female rats, then inhibition of allopregnanolone oxi-
dation by fluoxetine treatment would be expected to elevate
the concentration of this steroid. As mentioned in the Intro-
duction, we used male rat brain for studies of native 3α-HSD
to avoid possible fluctuations in activity during the ovarian
cycle. Clearly, further studies are now required to characterize
the effects of fluoxetine on allopregnanolone metabolism in
the female brain at different stages of this cycle.
When tested at the IC50 concentration of 240 μM for
fluoxetine, both norfluoxetine and imipramine inhibited the
oxidative 3α-HSD activity of rat brain microsomes and of
expressed human RoDH4. Norfluoxetine is the major active
metabolite of fluoxetine found in brain and has been
reported to be more potent than the parent drug for elevation
of mouse brain allopregnanolone (Pinna et al., 2003).
However, our results for the tricyclic imipramine were sur-
prising as systemic administration of this drug was reported
to have no effect on rat or mouse brain allopregnanolone
content (Uzunov et al., 1996; Pinna et al., 2003). Dosages of
imipramine used in the latter studies are unlikely to have
produced whole brain concentrations of this drug greater
than 20 μM (Sugita et al., 1989), at least 10-fold lower than
tested here against the oxidative 3α-HSD activity of the rat
brain microsomal fraction and human RoDH4. Thus, our
results with imipramine are probably not of therapeutic rel-
evance but are nonetheless consistent with the report that
50 μM imipramine reduces the Vmax for oxidation of allopreg-
nanolone by recombinant rat type 1 3α-HSD in vitro (Griffin
and Mellon, 1999). Moreover, the tetracyclic antidepressant
mirtazapine, which elevates plasma allopregnanolone in
humans, has also been shown to inhibit the overexpressed
human microsomal 3α-HSD oxidizing allopregnanolone to
5α-dihydroprogesterone with an IC50 of 46 μM, yet have no
effect at up to 50 μM on the recombinant human cytosolic
type 3 (AKR1C2) 3α-HSD catalyzing the reduction of
5α-dihydroprogesterone to allopregnanolone (see Schule
et al., 2006).
We selected a concentration of 50 μM for initial tests of
fluoxetine against 3α-HSD activity because this was the con-
centration used in the conflicting reports of Griffin and
Mellon (1999) and Trauger et al. (2002). It is also close to the
steady-state concentration of 21 μM reached for fluoxetine in
human brain during a typical 20 mg·day−1 p.o. adult dosing
schedule (Henry et al., 2005). As for the dosage of fluoxetine
given to the rats in the present study, this was chosen as the
treatment we have shown previously to prevent the stress-
induced hyperalgesia associated with the progesterone with-
drawal of late dioestrus (AJ Devall et al., submitted) and
would be expected to produce brain concentrations in the
region of 10 μM for both fluoxetine and norfluoxetine (Qu
et al., 2009). From studies of fluoxetine and norfluoxetine in
mice, Pinna et al. (2004; 2003) conclude that these SSRIs
elevate brain allopregnanolone content at doses below those
necessary for inhibition of 5-HT reuptake ex vivo. A similar
situation appears to hold in the rat, where doses as used
in the present study have no effect on the amount of extra-
cellular 5-HT collected by microdialysis in the dorsal
periaqueductal grey in vivo (AJ Devall et al., submitted). Anti-
depressant actions of SSRIs mediated at least in part through
5-HT reuptake inhibition often require 3–8 weeks of treat-
ment, during which down-regulation of 5-HT autoreceptors,
adrenoreceptors and other changes are thought to occur (see
Racagni and Popoli, 2008). By contrast, PMDD patients
respond to fluoxetine within 2 days (Steinberg et al., 2012), as
would be expected for a response mediated by the acute
inhibition of RoDH enzymes documented in the present
study.
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To conclude, our results indicate that fluoxetine elevates
the concentration of the neuroactive steroid allopregna-
nolone in the female rat brain not by enhancing its synthesis
from 5α-dihydroprogesterone but by inhibiting its oxidation
back to this inactive precursor by microsomal RoDH
enzymes. As such, fluoxetine might be better described as a
selective intracrine modulator (see Penning, 2011) than a
selective brain steroidogenic stimulant (Pinna et al., 2006).
Most importantly however, the present study identifies a new
site of action for fluoxetine, with implications for the devel-
opment of more selective agents and/or dosing regimens to
raise brain allopregnanolone, thereby offering the potential
to treat disorders of progesterone withdrawal such as PMDD
and post-partum depression.
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